Interaction of translationally controlled tumor protein with Apaf-1 is involved in the development of chemoresistance in HeLa cells by Jaehoon Jung et al.
Jung et al. BMC Cancer 2014, 14:165
http://www.biomedcentral.com/1471-2407/14/165RESEARCH ARTICLE Open AccessInteraction of translationally controlled tumor
protein with Apaf-1 is involved in the
development of chemoresistance in HeLa cells
Jaehoon Jung, Hyo Young Kim, Jeehye Maeng, Moonhee Kim, Dong Hae Shin and Kyunglim Lee*Abstract
Background: Translationally controlled tumor protein (TCTP), alternatively called fortilin, is believed to be involved
in the development of the chemoresistance of tumor cells against anticancer drugs such as etoposide, taxol, and
oxaliplatin, the underlying mechanisms of which still remain elusive.
Methods: Cell death analysis of TCTP-overexpressing HeLa cells was performed following etoposide treatment to
assess the mitochondria-dependent apoptosis. Apoptotic pathway was analyzed through measuring the cleavage
of epidermal growth factor receptor (EGFR) and phospholipase C-γ (PLC-γ), caspase activation, mitochondrial
membrane perturbation, and cytochrome c release by flow cytometry and western blotting. To clarify the role of
TCTP in the inhibition of apoptosome, in vitro apoptosome reconstitution and immunoprecipitation was used.
Pull-down assay and silver staining using the variants of Apaf-1 protein was applied to identify the domain that is
responsible for its interaction with TCTP.
Results: In the present study, we confirmed that adenoviral overexpression of TCTP protects HeLa cells from cell
death induced by cytotoxic drugs such as taxol and etoposide. TCTP antagonized the mitochondria-dependent
apoptotic pathway following etoposide treatment, including mitochondrial membrane damage and resultant
cytochrome c release, activation of caspase-9, and -3, and eventually, the cleavage of EGFR and PLC-γ. More
importantly, TCTP interacts with the caspase recruitment domain (CARD) of Apaf-1 and is incorporated into the
heptameric Apaf-1 complex, and that C-terminal cleaved TCTP specifically associates with Apaf-1 of apoptosome in
apoptosome-forming condition thereby inhibiting the amplification of caspase cascade.
Conclusions: TCTP protects the cancer cells from etoposide-induced cell death by inhibiting the mitochondria-mediated
apoptotic pathway. Interaction of TCTP with Apaf-1 in apoptosome is involved in the molecular mechanism
of TCTP-induced chemoresistance. These findings suggest that TCTP may serve as a therapeutic target for
chemoresistance in cancer treatment.
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Translationally controlled tumor protein (TCTP), also
called fortilin, P23, and histamine-releasing factor (HRF),
is a housekeeping protein, highly conserved in humans
to plants, has been shown to play pleiotropic func-
tions in cell growth, proliferation, and apoptosis among
others, in response to wide-ranging signals (reviewed
in [1]). Our earlier work [2], has shown that post-* Correspondence: klyoon@ewha.ac.kr
Graduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha
Womans University, Seoul 120-750, Korea
© 2014 Jung et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.translational modifications of TCTP such as proteoly-
sis and dimerization are prerequisites that endow TCTP
with its plethora of functions.
TCTP is significantly overexpressed in tumor cells while
suppression of TCTP expression enhances apoptosis
and causes reversion of transformed cells to their normal
phenotype [3-5]. TCTP exhibits its anti-apoptotic func-
tions [3] through mechanisms that stabilize the anti-
apoptotic Bcl-2 family protein, MCL1 [6] and that
antagonize the dimerization of pro-apoptotic Bax [7].
The N-terminal region of TCTP is known to be involvedd. This is an Open Access article distributed under the terms of the Creative
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totic Bcl-xL [8]. As a Ca2+-binding protein [9], TCTP seques-
ters the intracellular Ca2+ to perturb the Ca2+-dependent
apoptosis [10]. In addition, recent reports suggest that
TCTP represses the tumor suppressor p53 in a reciprocal
mode [11,12]. We recently showed that Na,K-ATPase,
an interacting partner in tumorigenesis, directly asso-
ciates with TCTP to induce human breast epithelial
cell transformation through Src-dependent EGFR transac-
tivation [13].
Also, it has been reported that TCTP overexpression
induces chemoresistance by protecting the various tumor
cells against DNA-damaging agents such as etoposide or
5-fluorouracil and against tunicamycin-induced endoplas-
mic reticulum (ER) stress [3,14,15]. Of interest, increased
expression of TCTP is revealed to have an interrelation
with increased chemoresistance, of malignant melanoma
to cytotoxic agents such as etoposide and its increased
survival [16]. In addition, a temporal proteome profiling
upon taxol exposure, revealed increased TCTP expression
during apoptosis [17]. Studies of colon cancer cell re-
sponse to oxaliplatin treatment revealed temporal upregu-
lation of TCTP [18]. However, little is known about the
unique molecular mechanisms in the role of TCTP in
the development of the chemoresistance of tumor
cells against anticancer drugs such as etoposide, taxol,
and oxaliplatin.
In this context, the role of deregulation or defects of
apoptosome function in the development of chemoresis-
tance [19], needs consideration as most anticancer drugs
suggested to mediate cell death via mitochondrial apop-
totic pathway [20]. For example, inactivation or silencing
of apoptotic protease activating factor (Apaf-1), has been
implicated in the development of chemoresistance [21]
by metastatic malignant melanomas [22]. Inhibition of
Apaf-1 provides a preferential survival advantage to neo-
plastic cells [23] and the lack of cytosolic Apaf-1 due to
its sequestration in lipid raft is noted as a new mechan-
ism of chemoresistance in B lymphoma [24]. Acquired
cisplatin resistance is partially reversed when Apaf-1 is
exogenously overexpressed in HeLa cells [25]. Further-
more, it has been shown that apoptosome-dependent
apoptosis can be inhibited when Apaf-1 is exposed to
endogenous regulators including Bcl-xL [26], Heat shock
protein 70 (HSP 70) [27], and Apaf-1 interacting protein
(APIP) [28].
We hypothesize that TCTP may be another possible
regulator of Apaf-1 that binds to Apaf-1 to incorporate
into apoptosome complex. In the present study we tested
this hypothesis by investigating whether TCTP involves
in the development of chemoresistance in mitochondria-
mediated apoptosis. We specifically examined the role of
TCTP in apoptosome inhibition, by studying its structural
modification in etoposide-treated cancer cells.Methods
Reagents and antibodies
Antibody detecting anti-Na,K-ATPase α1 subunit was pur-
chased from Upstate (Billerica, MA). Anti-PLC-γ, -actin,
-His, -cytochrome c, -caspase-9, -cleaved caspase-3, -cleaved
caspase-7, -cleaved caspase-9, -cleaved PARP, -Flag, and
-Apaf-1 antibodies were from Cell Signaling Technology
(Boston, MA). Anti-EGFR, and -GFP antibodies were
from Santa Cruz (Santa Cruz, CA). Anti-TCTP-specific
antibody was from LabFrontier (Korea). 5,5′,6,6′-tet-
rachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine
iodide (JC-1) was from Molecular Probe (Carlsbad, MO).
Etoposide, Taxol (paclitaxel), Ac-LEHD and Ac-DEVD
were from Calbiochem (San Diego, CA). Bovine serum al-
bumin (BSA), dATP, cytochrome c, and carbonyl cyanide
m-chlorophenylhydrazone (CCCP) were from Sigma
(St Louis, MO). Anti-OxPhos Complex IV (COX IV)
antibody was from Invitrogen (Carlsbad, CA). Purified
WD Repeat (WDR) protein was from Abnova Corporation
(Taiwan).Cell culture and infection
HeLa cells that were from American Type Culture
Collection (ATCC) were maintained and cultured in a
Dulbecco’s modified Eagle medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS), penicillin
(100 U/ml), and streptomycin (100 μg/ml). Cells were
placed at 37°C in a 5% CO2 atmosphere incubator
with humidification. For adenoviral expression, cells
were infected with 10 multiplicity of infection (MOI)
of adenoviruses containing N-terminal Flag-tagged TCTP
or C-terminal GFP-tagged TCTP genes, or with its corre-
sponding null virus for 2 h in DMEM without serum at
37°C in 5% CO2, followed by 20 h incubation in DMEM
media containing 10% serum. The cells were then serum-
starved for 2 h prior to drug treatment. The level of TCTP
overexpression was determined by western blot analysis.
Etoposide (20 μM) was administered after infection of
adenovirus.Cell death analysis
For detection of apoptosis, HeLa cells were seeded onto
12-well plates and treated with etoposide (20 μM) or
taxol (0.1 μM) for an indicated time. To measure the
DNA fragmentation by apoptosis, cells were stained
with propidium iodide (PI) and were assayed under
fluorescence-activated cell sorting (FACS) analysis.
Following the treatment with cytotoxic agents, HeLa cells
were harvested, and reconstituted in ice-cold phosphate
buffered saline (PBS) supplemented with 50 μg/ml of PI.
Samples were then detected their fluorescence by flow cy-
tometry (FACS Calibur, BD) and the results were analyzed
using WinMDI software.
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Under the presence of dATP and cytochrome c, HeLa
S-100 extract was incubated with recombinant human
TCTP for 1 h at 4°C in PBS. The reaction mixtures
were subjected to preclearance by adding Protein G-
agarose (Roche, IN) and incubated for 3 h at 4°C on
a rocking platform, to remove the non-specific pro-
tein binding to agarose. After eliminating the Protein
G beads by centrifugation at 14,000 × g for 10 min
(4°C), anti-Apaf-1 antibody was incubated with Pro-
tein G-agarose for overnight, followed by the adding
of HeLa S-100 extract into the reaction mixture for
1 h (4°C). The immune complexes resulted were pel-
leted, washed three times with ice-cold PBS, reconsti-
tuted with SDS sample buffer and then resolved on
the SDS-PAGE. Western blotting of lysates from
GFP-tagged TCTP-overexpressing cells following eto-
poside treatment was performed by anti-GFP- and
protein-specific antibodies. Western blotting and im-
munoprecipitation of lysates from Flag-tagged adNull-
and adTCTP-infected cells following etoposide treat-
ment were performed by using anti-Na,K-ATPase α1,
Apaf-1 and protein-specific antibodies. Image of west-
ern blot was visualized and obtained using LAS-3000
image analysis system (Fujifilm Life Science).
In vitro activation of apoptosome formation
To obtain the S-100 extract, HeLa cells were harvested
through centrifugation. After washing the cells, cells
were then resuspended in buffer (1.5 mM MgCl2,
10 mM KCl, 20 mM HEPES (pH 7.5), 1 mM EGTA and
EDTA, 0.1 mM phenylmethylsulfonyl fluoride (PMSF),
10 μg/ml leupeptin/aprotinin, and 1 mM dithiothreitol
(DTT)). Then, reconstituted cells were homogenized
with a Dounce glass homogenizer, and the resultant cell
homogenates were subjected for centrifugation at 10,000 ×
g for 10 min (4°C) to extract the nuclear and mitochon-
drial organelles. The supernatants containing S-100 frac-
tion were obtained and were mixed with 1 mM dATP/
10 μM cytochrome c at a 2.5 mM Mg2+ concentration.
Where indicated, recombinant TCTP protein was supple-
mented in the reaction mixture.
Isolation of cytosolic and mitochondrial fractions
Following centrifugation, cells were harvested and the
mitochondrial and cytosolic fractions were isolated using
commercial kit (Pierce Biotechnology) according to the
manufacturer’s instructions. In brief, cells were incu-
bated with Reagent A for 2 min on ice and then trans-
ferred to Dounce homogenizer for homogenization (20
strokes). After adding the Reagent C, the mixtures were
then centrifuged at 700 × g for 10 min at 4°C. The super-
natant were then collected and further centrifuged at
3,000 × g for 15 min at 4°C to pellet the mitochondria.The resulting supernatant was designated as cytosolic
fraction and the mitochondrial precipitate was washed
with Reagent C followed by centrifugation at 12,000 × g
for 5 min at 4°C. The purity of cytosolic and mitochon-
drial fractions was confirmed by the western blotting
by detecting the immunoactivity of actin and COX
IV, respectively.
Measurement of cytochrome c release
Cytochrome c release was measured by western blotting
or quantified using a fluorescent dye. Following the
isolation of cytosolic and mitochondrial fractions from
HeLa cells as described above, cytochrome c contents
in each fraction were analyzed by immunoblot ana-
lysis using anti-cytochrome c-specific antibody (Cell
Signaling Technology). To quantify the cytochrome c re-
lease, cells were mixed with a buffer containing 20 mM
HEPES, 10 mM KCl, 1.5 mM MgCl2, 1 mM EGTA and
EDTA, 1 mM AEBSF, 8 mM DTT, and 250 mM sucrose,
supplemented with digitonin. Then the cells were har-
vested and subjected for fixation using 4% formaldehyde/
1% fetal calf serum (FCS) solution. Permeabilized cells
were incubated with 10% FCS in phosphate buffer and
reacted with fluorescence-tagged anti-cytochrome c anti-
body. Cells were then washed and analyzed using flow
cytometry (FACS Calibur, BD). Data obtained were
presented in relative fluorescent units (RFUs).
Analysis of mitochondrial membrane potential
To determine the perturbation of mitochondrial mem-
brane potential (ΔΨm), the fluorescent cationic dye,
5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolylcar-
bocyanine iodide (JC-1, Molecular Probes) was used with
FACS. The red-to-green ratio of JC-1 fluorescence is de-
tected to probe the ΔΨm. When the integrity of mitochon-
drial membrane is maintained with high potential, JC-1
forms aggregates with red-fluorescence. But the perturb-
ation of mitochondrial membrane leads it to emit only
green fluorescence because of the loss of membrane po-
tential. The mitochondrial membrane uncoupler, carbonyl
cyanide m-chlorophenylhydrazone (CCCP), was used as a
positive control that disturbs the mitochondrial mem-
brane potential. After loading the HeLa cells with JC-1 at
37°C, cells were analyzed by FACS (FACS Calibur, BD)
using FL-1 (JC-1 monomer, green) and FL-2 (JC-1 aggre-
gate, red) channels.
Identification of TCTP binding domain on Apaf-1
Several Apaf-1 deletion mutants that contain C-terminal
His-tags were designed and constructed by referencing
the previous study [29]. Recombinant proteins including
Full APAF-1, APAF-530, APAF-420, and APAF-97 were
expressed in BL21(DE3)pLysS Escherichia coli and puri-
fied through affinity purification on a Ni Sepharose
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tained from Abnova Corporation. GST-tagged recom-
binant TCTP protein was bacterially expressed in E.coli
system and purified using GST fusion protein purifica-
tion kit (Thermo Scientific). Purified His-Apaf-1 variants
or WDR were immobilized on Handee™ spin column
(PIERCE, IL) and then incubated with TCTP-GST pro-
tein. Each eluates were separated by SDS-PAGE and
then subjected for silver staining.
Results
TCTP inhibits drug-induced cell death by inhibiting the
fragmentation of EGFR and PLC-γ
We attempted to clarify the antiapoptotic role of TCTP
in the development of chemoresistance to etoposide, an
inhibitor of topoisomerase II, as well as taxol (pacli-
taxel), a microtubule stabilizer, those are widely used an-
ticancer drugs with distinctive modes of action. Human
TCTP gene was overexpressed in human cervical cancer
cells (HeLa) using adenoviral infection and apoptosis
was measured by DNA fragmentation using propidium
iodide (PI) staining and fluorescence-activated cell sort-
ing (FACS). We found that treatment with both etopo-
side and taxol increased cell death in HeLa cells. When
TCTP was overexpressed, cell death decreased from 68%
to 11%, in etoposide-treated HeLa cells and from 71% to
13%, in taxol-treated HeLa cells (Figure 1A), confirming
that TCTP inhibits cytotoxicity and cell death induced
by two anticancer drugs.
It has been suggested that etoposide as well as taxol
cause apoptosis via caspase activation [30,31]. Because
EGFR and PLC-γ are known to be cleaved by caspases
during apoptotic process [32,33], we examined whether
TCTP also inhibits the fragmentation of these proteins.
Figure 1B shows that treatment of cells with etoposide
resulted in the fragmentation of both EGFR and PLC-γ
and that overexpression of TCTP decreased such frag-
mentations. Taken together, these findings suggest that
TCTP enabled the HeLa cells to acquire chemoresis-
tance in etoposide-induced apoptosis possibly through
inhibition of initiator or effector caspase activity thereby
preserving the key players for tumor cell function such
as EGFR and PLC-γ.
TCTP inhibits mitochondrial membrane perturbation
thereby reducing cytochrome c release from
mitochondria to cytosol in etoposide-induced cell death
Following Bax translocation to mitochondria, release of
intermembrane cytochrome c lead to the perturbation of
the mitochondrial membrane potential by disturbing the
electron transfer [34]. We tested whether TCTP inhibits
mitochondrial membrane polarization during etoposide-
induced cell death. Flow cytometry, employing the dye,
JC-1, an indicator for mitochondrial membrane potential,showed that the distribution of membrane potential is
normal in untreated HeLa cells (Figure 2A). In contrast,
the distribution of membrane potential shifted from red
(FL-2) to green (FL-1) fluorescence when carbonyl cyanide
m-chlorophenylhydrazone (CCCP), a protonophore, was
treated as a positive control, through its effects on mito-
chondrial uncoupling (Figure 2A). Interestingly, hyperpo-
larized distribution of mitochondrial membrane potential
in etoposide-induced cell death was inhibited by TCTP
overexpression (Figure 2A).
Next, we examined if TCTP also inhibits cytochrome
c release under genotoxic stress. As shown in Figure 2B,
the content of cytochrome c was higher in the cytosolic
fraction of etoposide-treated HeLa cells than in un-
treated cells. In contrast, TCTP overexpression inhibited
the cytochrome c release from mitochondria to cytosolic
fraction in etoposide-treated HeLa cells (Figure 2B), as also
confirmed by the fluorimetry analysis using fluorescence-
tagged anti-cytochrome c antibody (Figure 2C). There-
fore, TCTP appears to induce the chemoresistance of
etoposide-induced cell death by inhibiting the mitochon-
drial membrane damage (Figure 2A) and the resultant cyto-
chrome release into cytosolic fraction (Figure 2B and C).
TCTP inhibits caspase activation in etoposide-induced cell
death
Release of cytochrome c from mitochondria, induces the
formation of functional apoptosome that signals the acti-
vation of caspase cascade in the mitochondria-dependent
apoptotic pathway [35,36]. Apoptosome cleaves apical
caspase-9, which in turn induces the activation of caspases
-3 and -7 to execute the dismantling of the cells (reviewed
in [37]) through proteolysis of its target proteins such as
poly ADP ribose polymerase (PARP) [38]. In etoposide-
treated human melanoma cells, cytochrome c release was
observed along with upregulation of caspases -9 and -3
[39]. Because TCTP inhibits cytochrome c release from
the mitochondria, effects on caspase activity by TCTP
were investigated by specifically detecting the cleaved
form of caspases. As presented in Figure 3A, etoposide
treatment induced cleavage of caspase -9, -3, and -7 as
well as fragmentation of its target PARP in HeLa cells.
Adenoviral overexpression of TCTP inhibited the produc-
tion of all of these fragments except for the 35 kDa of
caspase-9 (Figure 3A, right panel) in etoposide-treated
cells.
Reconstitution of the caspase activation in vitro was
performed to confirm the inhibitory effect of TCTP on
the caspase activity. In the presence of cytochrome c
and dATP, Apaf-1 oligomerizes to assembly into a hepta-
meric apoptosome complex [35]. Cytosolic environment
of apoptosome assembly was artificially reconstituted by
using S-100 extracts that is mitochondria-depleted cyto-
solic fraction of HeLa cells. Only when both dATP and
A
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Figure 1 TCTP inhibits anticancer drug-induced cell death and cleavage of EGFR and PLC-γ in HeLa cells. (A) TCTP-induced inhibition of
cytotoxic drug-induced cell death. AdNull- and adTCTP-infected HeLa cells (MOI, 10) were incubated with 20 μM etoposide or 0.1 μM taxol and
then DNA fragmentation was analyzed using PI staining and FACS as described in Materials and Methods. (B) TCTP-induced inhibition of cytotoxic
drug-induced EGFR and PLC-γ fragmentation. After treatment of 20 μM etoposide or 0.1 μM taxol, adGFP (G)- and adTCTP-GFP (T)-infected HeLa
cell (MOI, 10) extracts were blotted with anti-EGFR, -PLC- γ, and -GFP antibodies.
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Apaf-1 monomer in S-100 extract formed an apopto-
some in vitro thereby producing the cleaved form of
caspase-9 and caspase-3 (Figure 3B). Consistent with the
result in Figure 3A, preincubation of recombinant TCTP
with the reaction mixture attenuated the activation ofcaspase-9 as well as caspase-3 (Figure 3B). To note,
cleaved form of TCTP was detected when S-100 was
incubated with TCTP (Figure 3B and Additional file 1:
Figure S1).
To ascertain the effect of TCTP on caspase activity,
caspase-specific inhibitors were added into the reactions
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Figure 2 TCTP inhibits mitochondrial cytochrome c release and mitochondrial membrane depolarization in etoposide-induced cell
death. (A) TCTP-induced inhibition of mitochondrial membrane perturbation. AdNull and adTCTP-infected cells (MOI, 10) were treated with
20 μM etoposide. Loss of mitochondrial membrane potential was measured using JC-1 dye by flow cytometry. The disrupter, CCCP was used as a
positive control. JC-1 forms aggregates in the high mitochondrial membrane potential whereas the disrupted potential during apoptosis leads to
form the JC-1 monomer. Loss of membrane potential was detected by measuring the shift of fluorescence from FL-2 (JC-1 aggregates, red
fluorescence) to FL-1 (JC-1 monomers, green fluorescence) in FACS analysis. (B) TCTP-induced inhibition of mitochondrial cytochrome c release.
AdGFP (G)- and adTCTP-GFP (T)-infected cells (MOI, 10) were treated with 20 μM etoposide. After fractionation of mitochondrial and cytosolic
fractions, anti-cytochrome c antibodies were used for detecting its contents by western blot analysis. (C) Cytochrome c release was quantitated
by expressing as RFU. AdGFP (G)- and adTCTP-GFP (T)-infected cells (MOI, 10) were treated with 20 μM etoposide. Following incubation with
fluorescence-tagged cytochrome c-specific antibody, cells were subjected to FACS analysis. Data represent cytochrome c release relative to the
control (mean ± S.D.) of two independent experiments.
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substrate that emits fluorescence when caspases cleave
it. Caspase-9-specific inhibitor, Ac-LEHD, in S-100 with
dATP/cytochrome c decreased the caspase-9 activity to
an extent comparable to that of S-100 control (Figure 3C,
upper panel). Addition of TCTP protein reduced the
caspase-9 activity specifically in apoptosome-formingcondition, while BSA, a protein control, had a minimal
effect compared to that of control (Figure 3C, upper
panel). TCTP also inhibited caspase-3 in apoptosome-
containing cells to the similar extent as caspase-3 inhibi-
tor, Ac-DEVD-treated cells (Figure 3C, lower panel). As
shown in Figure 3D, TCTP inhibited caspase-9, and -3






























S-100 + + + + + +
TCTP + + + +































Control Ac-LEHD BSA TCTP
D















































0     0.01    0.1   1   10
Figure 3 (See legend on next page.)
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Figure 3 TCTP inhibits caspase activation in etoposide-induced cell death. (A) TCTP-induced inhibition of caspase-9, -7, and -3 fragmentation.
AdGFP (G)- and adTCTP-GFP (T)-infected cells (MOI, 10) were treated with 20 μM etoposide and the activation of caspases were determined by western
blot assay using cleaved form-specific caspase-9, -7, and -3, and PARP antibodies (left panel). Cleavage of procaspase-9 was further assayed using
specific antibodies detecting 35- and 37-kDa form of cleaved caspase-9 (right panel). (B) TCTP-induced inhibition of caspase-9 and -3 cleavages under
in vitro assays of apoptosome reconstitution. S-100 extracts were incubated with dATP/cyto c to induce the apoptosome formation. Activation of
caspase-9 and -3 was detected by western blotting in the presence or absence of TCTP in the reaction. (C) TCTP-induced inhibition of caspase-9
and -3 activities confirmed by inhibitor assay. The specific inhibitor of caspase-9 and -3, Ac-LEHD and Ac-DEVD, respectively, were used.
Caspase activity was presented as RFU by using fluorogenic substrates for caspases. Error bar represent SD of two independent experiments.
(D) Time- and dose-dependence of TCTP-induced inhibition of caspase-9 and -3 fragmentations. Following dose- and time-dependent incubation with
His-tagged TCTP at a time of 30 min and at a dose of 1 μg/ml, respectively, western blot assay was performed to detect caspase activity using
anti-Apaf-1, -cleaved caspase-9, -cleaved caspase-3, and -His-specific antibodies.
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of Apaf-1 in the apoptosome complex to inhibit the
activation of caspase-9
TCTP may exert its antiapoptotic activity by inhibiting
the caspase-9 activation in apoptosome, following etopo-
side treatment. To examine the mechanism of apopto-
some inhibition by TCTP, we investigated whether
TCTP interacts with Apaf-1 in vitro. S-100 extracts were
incubated with dATP and cytochrome c to assemble the
apoptosome, following pre-incubation with recombinant
TCTP protein. The resulting protein complex was immu-
noprecipitated with anti-Apaf-1-specific antibodies. We
found that Apaf-1 in S-100 extracts was bound to
procaspase-9, cytochrome c and addition of TCTP to the
mixture did not affect the binding of procaspase-9 and
cytochrome c to the Apaf-1 in vitro, suggesting that TCTP
did not inhibit the procaspase-9 binding to Apaf-1
(Figure 4A).
In order to identify which domain of Apaf-1 serves
as the binding site for TCTP, we generated variants
of full-length Apaf-1 devoid of some particular domain(s)
present in Apaf-1, for example APAF-530 (residues 1-530),
APAF-420 (residues 1-420), and APF-97 (residues 1-97)
(Figure 4B), as previously described [29]. Recombinant full
APAF-1 (residues 1-1194), APAF-530 (residues 1-530),
APAF-420 (residues 1-420), APF-97 (residues 1-97), and
TCTP-GST were expressed in Escherichia coli, and sub-
jected to affinity purification (Additional file 2: Figure S2).
His-tagged Apaf-1 variants were immobilized on a
spin column and then incubated with or without GST-
tagged TCTP. Silver staining of the eluates revealed that
TCTP interacts with all of Apaf-1 variants, suggesting
the interaction of TCTP at the site of Apaf-1 CARD
(Figure 4B). A parallel experiment using WD Repeat
(WDR), protein lacking CARD and CED-4 domains of
Apaf-1, confirmed that CARD domain serves the site
for TCTP binding to Apaf-1 (Figure 4B). Therefore, it
appears that TCTP itself interacts with CARD of Apaf-1
to assemble into the apoptosome without interrupting the
procaspase-9 binding to Apaf-1 in apoptosome-forming
condition.Fragmented TCTP specifically interacts with Apaf-1 in
etoposide-induced cell death
Since fragmented form of TCTP was a component of
in vitro reconstituted apoptosome complex (Figure 3B),
cleaved TCTP may presumably operate in association
with Apaf-1 in response to apoptotic trigger while full-
length TCTP interacts with Na,K-ATPase [40]. To differ-
entiate the interaction between Na,K-ATPase and TCTP
upon etoposide treatment, we performed immunopre-
cipitation using anti-Na,K-ATPase antibodies following
the adenoviral infection of N-terminal Flag-tagged TCTP.
As shown in Figure 5A, Na,K-ATPase interacted with full-
length TCTP and etoposide treatment had no effect on
this binding. When the Apaf-1-interacting molecules were
precipitated in parallel experimental settings, full-length
TCTP found to be associated with Apaf-1 in the TCTP-
overexpressing untreated cells. Treatment with etoposide
resulted in additional interaction of Apaf-1 with short-
length Flag-TCTP (Figure 5B).
Taken together these findings suggest that full-length
TCTP binds to Apaf-1 CARD both in normal and apop-
totic conditions whereas C-terminal cleaved TCTP (the
Flag-tagging is located in the N-terminal of TCTP) spe-
cifically binds to Apaf-1 under apoptosome-forming con-
ditions in TCTP overexpressed cells. It can be inferred
that when apoptotic signaling is introduced, cleaved form
of TCTP binds to Apaf-1 of apoptosome to interfere with
the activation of mitochondria-mediated cell death, while
full-length TCTP is responsible for Na,K-ATPase binding.
Discussion
Genotoxic stress or DNA damage resulting from chemo-
therapy activates the intrinsic apoptotic pathway which
includes a sequential cascade of events leading to cell
death. Defects in the apoptotic pathways have been asso-
ciated with tumorigenesis as well as resistance against
conventional chemotherapeutics [19]. Downregulation of
target enzyme topoisomerase II, modulation of micro-
RNA, and acquisition of multiple drug resistance (MDR)
phenotype through induction of mdr-1 and ABC trans-
porter genes [41-45] are the major known mechanism of
Figure 4 TCTP interacts with CARD of Apaf-1 to form an apoptosome complex. (A) Binding of TCTP to Apaf-1 in apoptosome-forming
condition. TCTP, procaspase-9, and cytochrome c binding to Apaf-1 was analyzed. Recombinant human TCTP, cytochrome c, dATP and S-100
extract were incubated, immunoprecipitated with anti-Apaf-1-specific antibody and then blotted with antibodies, as described in Methods.
(B) Interaction of TCTP with CARD of Apaf-1. Schematic diagram of full-length Apaf-1 and its variants devoid of particular domain(s) was
presented. The full-length Apaf-1 (residues 1-1194) contains CARD (residues 1-97), CED-4 (residues 98-412), and WD-40 repeats (residues 413-1194).
Recombinant Full APAF-1, APAF-530 (residues 1-530), APAF-420 (residues 1-420), APAF-97 (residues 1-97), and TCTP-GST (GST-tagged TCTP) were
constructed. Purified WDR (WD Repeat) protein lacking both CARD and CED-4 was obtained from Abnova Corporation. Binding of TCTP-GST and
His-tagged Apaf-1 constructs was analyzed using pull-down assay. Protein binding complexes were separated on SDS-PAGE and stained with silver.
Purified TCTP-GST protein was also resolved by SDS-PAGE for detection of TCTP (last lane). NC, negative control.










































Figure 5 Cleaved TCTP specifically binds to Apaf-1 during apoptosis. (A) Full-length TCTP binding to Na,K-ATPase α1 subunit in
TCTP-overexpressing HeLa cells in etoposide-induced cell death. Following treatment with 20 μM etoposide, Flag-tagged adNull- and
adTCTP-infected cell extracts (MOI, 10) were immunoprecipitated with anti-Na,K-ATPase α1-specific antibodies and blotted with anti-Flag-specific
antibody. (B) Fragmented TCTP binding to Apaf-1 in etoposide-induced cell death. Following treatment with 20 μM etoposide, Flag-tagged
adNull- and adTCTP-infected cell (MOI, 10) extracts were immunoprecipitated with anti-Apaf-1-specific antibody and blotted with
anti-Flag antibody.
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http://www.biomedcentral.com/1471-2407/14/165resistance to etoposide treatment in tumor cells. In the
present study, TCTP protected cancer cells from
etoposide-induced cytotoxicity via sequential regulation
of major events of mitochondrial apoptosis. TCTP over-
expression (a) reduced mitochondrial membrane damage
thereby preventing cytochrome c release into the cytosol;
(b) inhibited apoptosome functions including caspase-9 ac-
tivation, which in turn inhibited caspase-3; (c) perturbed
the cleavage of the proteolytic targets including EGFR and
PLC-γ; and (d) eventually inhibited cell death in etoposide-
treated HeLa cells.
Most importantly, TCTP seems to inhibit the etoposide-
induced cell death at the site of apoptosome formation viaassociation with Apaf-1. Though previous studies indi-
cated that abnormal function of Apaf-1 correlates with
loss of sensitivity upon cytotoxic therapy [46] and that up-
regulation of TCTP is also related to the pathogenesis of
chemoresistance in cancer cells [16], the exact molecular
mechanisms and interactions are unknown. One example
of negative regulation of apoptosome formation is the
finding that constitutive overexpression of HSP70 is re-
lated to the resistance to apoptosis exhibited by particular
tumor cells. HSP70 in part modulates the Apaf-1 function
through its direct association with the CARD of Apaf-1,
thereby inhibiting the oligomerization of Apaf-1 and asso-
ciation of Apaf-1 with procaspase-9 [47].
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are underway to test whether endogenous TCTP also
binds to Apaf-1 in HeLa cells. Because we observed
Apaf-1 binding and truncation of TCTP in a single cell
line following TCTP overexpression, other types of
etoposide-resistant cancer cells need to be explored for
verifying the Apaf-1-TCTP interaction. Perturbation of
apoptosis by Apaf-1-TCTP complex possibly involves
the direct mechanism that inhibits the apoptosome. In
addition, indirect mechanisms involving the regulation
of certain molecules in apoptotic pathway may consti-
tute the TCTP-induced chemoresistance. As HeLa cells
are reported to retain the p53-mediated pathway [48,49],
inhibition of p53 by TCTP is a possible mechanism that
contributes to the TCTP-induced chemoresistance through
the regulation of MDM2 or Bax. To clarify this, our future
work will include the study of TCTP-Apaf-1 interaction
using the p53-silenced cells.
Though TCTP associates with CARD region of Apaf-1
(Figure 4B) to which caspase-9 binds, this interaction
did not inhibit the caspase-9 binding to Apaf-1
(Figure 4A) but abolished the production of active
caspases (Figure 3B). Following etoposide treatment,
procaspase-9 was cleaved to 35 and 37 kDa fragments
(p35 and p37, respectively) but TCTP did not inhibit the
production of p35 (Figure 3A, right panel). Initially,
interaction of procaspase-9 with Apaf-1 induces auto-
cleavage at Asp-315 of procaspase-9 to produce the p35.
Once caspase-3 is activated by p35-containing apopto-
some, it mediates another cleavage of caspase-9 at Asp-
330, which produces p37 to amplify the apoptotic signal
via positive feedback on the remaining procaspase-9
[29,35,36,50]. Therefore, selective inhibition of TCTP on
the cleavage of procaspase-9 into p37 in etoposide-
treated cells indicates that TCTP may not be involved in
the initial auto-catalysis but inhibits the amplification of
caspase cascade as it interrupts the cleavage at Asp-330.
This observation is consistent with the finding that TCTP
did not inhibit the initial procaspase-9 interaction with
Apaf-1 (Figure 4A). Taken together, it can be postulated
that incorporation of cleaved TCTP into apoptosome
inhibits etoposide-induced apoptosis by preventing recruit-
ment of procaspase-3 to the apoptosome. In addition, the
mechanism how fragmented TCTP that comprises only a
small fraction of Apaf-1-binding TCTP in apoptosome
enables the protection of HeLa cells against etoposide-
induced toxicity remains to be addressed.
It can be inferred that some specific environment
might led to posttranslational modification of TCTP
possibly at its C-terminal. This possibility is supported
by prior observations that N-terminal region of TCTP is
necessary for its interaction with Bcl-xL for its antiapopto-
tic activity [8] and that extracellular N-terminal truncated
TCTP exhibits cytokine-like activities via its homo-dimerization [2]. Therefore, cleaved form TCTP might
contain N-terminal region and C-terminal fragments that
possibly induce changes of ternary structure of TCTP
which enable the association of Apaf-1 in apoptosome
complex. This implies that distinctive form of TCTP may
exist to separately interact with its different intracellular
partners. The structural modification of TCTP including
truncation or oligomerization, which may be provoked in
specific conditions, appears to be involved in the mechan-
ism for acquiring its pleiotropic activity.
Proteolytic enzymes, such as caspases, which are pref-
erentially activated upon apoptotic signals, are possibly
involved in the C-terminal cleavage of TCTP. However,
this possibility can be ruled out since the primary se-
quence of TCTP does not contain the enzymatic site for
caspase activity (data not shown). As only S-100 is com-
petent to cleave the TCTP (Additional file 1: Figure S1),
apoptosome formation is not necessary for its cleavage.
We tested various kinds of protease inhibitors including
VAD (a pan-caspase inhibitor), LDESD (a caspase-2/3 in-
hibitor), DEVD (a caspase-3 inhibitor), LEHD (a caspase-9
inhibitor), and MG132 (an inhibitor for calpain/proteasome)
and found that cleavage of TCTP was not prevented by
those agents. It is also supported by the evidence that re-
combinant caspase-3 did not cleave recombinant TCTP
in vitro whereas it produces the cleavage of known sub-
strate PARP [51]. Furthermore, S-100 treated with Apaf-1
domain-specific blocking antibodies as well Ca2+, followed
by TCTP addition, caused the fragmentation of TCTP
(data not shown). How TCTP becomes fragmented and
which residues in TCTP are subjected to cleavage are
under investigation.
Because TCTP is regarded as an oncogene and is up-
regulated in tumors, reducing the TCTP levels or inhibit-
ing its activity, are viewed as alternative rational approaches
in cancer therapy. Recently, the pathophysiological associ-
ation of high-TCTP status with poor prognosis in a large
cohort of breast cancer patients was demonstrated [11].
Also, TCTP inactivation by pharmacological compounds
has been studied as modalities of cancer therapy. For ex-
ample, antidepressant sertraline and neuroleptic thiorida-
zine, both of which restore p53, directly bind to TCTP to
suppress TCTP-mediated activation of the p53 ubiquitina-
tion [11] and reduce the intracellular contents of TCTP,
thus promoting apoptosis in tumor cells [52]. TCTP-
binding antimalarial drug, artemisinin derivatives are be-
ing investigated as antitumor agents that have been tried
as therapeutics in patients [53,54].
Most known functions of TCTP are related to its spe-
cific association with a variety of interacting molecules.
The present study identified TCTP as a hitherto unknown
partner of Apaf-1, and that it has a special role in the
apoptosis induced by anticancer agents. It is logical to
propose TCTP as a potential target of chemoresistance
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http://www.biomedcentral.com/1471-2407/14/165therapy because TCTP is shown to be incorporated
into apoptosome complex to inhibit the etoposide-
induced cell death. Therefore, the emerging picture
from results described herein harnesses TCTP as po-
tentially important clinical and pharmacological target
not only in tumorigenesis but also in refractory can-
cers against chemotherapeutics.
Conclusions
The current study indicates that TCTP is involved in the
inhibition of etoposide-induced mitochondrial apoptosis
in HeLa cells by perturbing the major events of the
apoptotic pathway. In addition, TCTP is shown to interact
with Apaf-1 CARD and is incorporated into the apopto-
some complex in the apoptosome-forming conditions,
thereby inhibiting the amplification of caspase cascade.
Therefore, modulation of TCTP can be suggested as a po-
tential strategy in the development of drugs to treat the
tumorigenesis as well as chemoresistance.
Additional files
Additional file 1: Figure S1. Cleavage of TCTP in S-100 extracts. To
elucidate the necessary requirements for cleavage of TCTP, recombinant
TCTP protein was incubated with various compositions of HeLa S-100
extracts, dATP, and cytochrome c. After incubation, the reaction mixtures
were immunoblotted with anti-His-specific antibody.
Additional file 2: Figure S2. Preparation of TCTP, Apaf-1 and its
variants. TCTP, Apaf-1 and its variants were expressed in Escherichia coli
system. Proteins were purified using its His- or GST-tagging on an affinity
purification column, separated by 10% SDS-PAGE, and analyzed using the
Silver Stain Plus kit.
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